Sensitization of Drug Resistant Cancer Cells: A Matter of Combination Therapy

• Main Authors: Meghan Leary, Sarah Heerboth, Karolina Lapinska, Sibaji Sarkar
• Format: Article
• Language: English
• Published: MDPI AG 2018-12-01
• Series: Cancers
• Subjects: cancer drug sensitization; drug resistance; combination therapy; stem cell; cancer progenitor cell; cancer therapy; chemotherapy; epigenetics; methylation; histone modification
• Online Access: https://www.mdpi.com/2072-6694/10/12/483

Cancer drug resistance is an enormous problem. It is responsible for most relapses in cancer patients following apparent remission after successful therapy. Understanding cancer relapse requires an understanding of the processes underlying cancer drug resistance. This article discusses the causes of cancer drug resistance, the current combination therapies, and the problems with the combination therapies. The rational design of combination therapy is warranted to improve the efficacy. These processes must be addressed by finding ways to sensitize the drug-resistant cancers cells to chemotherapy, and to prevent formation of drug resistant cancer cells. It is also necessary to prevent the formation of cancer progenitor cells by epigenetic mechanisms, as cancer progenitor cells are insensitive to standard therapies. In this article, we emphasize the role for the rational development of combination therapy, including epigenetic drugs, in achieving these goals.